Author: Lei Deng, MD PGY-6 Fellow of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor at UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 3, 2023 8am
Author: Lei Deng, MD PGY-6 Fellow of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor at UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 3, 2023 8am
Author: Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor At UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 4, 2023 Overall survival analysis from the ADAURA trial
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk